Previous studies have reported that PET/CT imaging targeting GRPR has a sensitivity of approximately 70% for lymph node metastasis in prostate cancer patients, but previous study only included three patients with a total of ten lymph node metastases. The gene discussed is GRPR; the disease is metastatic malignant neoplasm in the lymph nodes.